$8.76 0.14 (+1.62%)
2/13/2012 10:13 AM

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CAPS Rating: 2 out of 5

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

Featured Broker Partners


Advertisement